Edward Fitzgerald
Direktor/Vorstandsmitglied bei Fog Pharmaceuticals, Inc.
Profil
Edward M.
Fitzgerald is currently a Director at Fog Pharmaceuticals, Inc. He was previously an Independent Director at Akcea Therapeutics, Inc. from 2017 to 2020, and the Chief Financial Officer, Treasurer & Executive VP at ARIAD Pharmaceuticals, Inc. from 2011 to 2016.
Prior to that, he was the Chief Financial Officer, Secretary & Senior VP at AltaRex Medical Corp.
from 1998 to 2002, and a Partner at Arthur Andersen LLP from 1989 to 1992.
Mr. Fitzgerald received his undergraduate degree and MBA from Babson College.
Aktive Positionen von Edward Fitzgerald
Unternehmen | Position | Beginn |
---|---|---|
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Edward Fitzgerald
Unternehmen | Position | Ende |
---|---|---|
AKCEA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2020 |
ARIAD PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 21.03.2016 |
AltaRex Medical Corp.
AltaRex Medical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Endo International Plc, AltaRex Medical Corp. develops and researches foreign antibodies for cancer and life-threatening disease treatment. The company is based in Edmonton, Canada. AltaRex Medical was acquired by ViRexx Medical Corp., part of Endo International Plc from December 23, 2008 on December 13, 2004 for $22.66 million. | Finanzdirektor/CFO | 01.04.2002 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Corporate Officer/Principal | 01.01.1992 |
Ausbildung von Edward Fitzgerald
Babson College | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
AltaRex Medical Corp.
AltaRex Medical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Endo International Plc, AltaRex Medical Corp. develops and researches foreign antibodies for cancer and life-threatening disease treatment. The company is based in Edmonton, Canada. AltaRex Medical was acquired by ViRexx Medical Corp., part of Endo International Plc from December 23, 2008 on December 13, 2004 for $22.66 million. | Commercial Services |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |